Tags

Type your tag names separated by a space and hit enter

Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Fertil Steril. 2017 02; 107(2):457-466.e9.FS

Abstract

OBJECTIVE

To determine the genomic signatures of human uterine leiomyomas and prevalence of MED12 mutations in human uterine leiomyosarcomas.

DESIGN

Retrospective cohort study.

SETTING

Not applicable.

PATIENT(S)

This study included a set of 16 fresh frozen leiomyoma and corresponding unaffected myometrium specimens as well as 153 leiomyosarcomas collected from women diagnosed with uterine leiomyomas or leiomyosarcomas who underwent clinically indicated abdominal hysterectomy.

INTERVENTION(S)

None.

MAIN OUTCOME MEASURE(S)

Whole exome sequencing and high-resolution X-chromosome and whole genome single nucleotide polymorphism microarray analyses were performed on leiomyoma samples negative for the known MED12 mutations and compared with their corresponding myometrium. Leiomyosarcoma specimens were examined for exon 2 MED12 mutations to evaluate the frequency of MED12 mutated leiomyosarcomas.

RESULT(S)

Our results indicate remarkable genomic heterogeneity of leiomyoma lesions. MED12-negative leiomyomas contain copy number alterations involving the Mediator complex subunits such as MED8, MED18, CDK8, and long intergenic nonprotein coding RNA340 (CASC15), which may affect the Mediator architecture and/or its transcriptional activity. We also identified mutations in a number of genes that were implicated in leiomyomagenesis such as COL4A6, DCN, and AHR, as well as novel genes: NRG1, ADAM18, HUWE1, FBXW4, FBXL13, and CAPRIN1.

CONCLUSION(S)

Mutations in genes implicated in cell-to-cell interactions and remodeling of the extracellular matrix and genomic aberrations involving genes coding for the Mediator complex subunits were identified in uterine leiomyomas. Additionally, we discovered that ∼4.6% of leiomyosarcomas harbored MED12 exon 2 mutations, but the relevance of this association with molecular pathogenesis of leiomyosarcoma remains unknown.

Authors+Show Affiliations

Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pathology, Magee-Women's Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania; Magee-Women's Research Institute, Pittsburgh, Pennsylvania; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.Department of Pathology, Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.Department of Pathology, Magee-Women's Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pathology, Magee-Women's Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania; Magee-Women's Research Institute, Pittsburgh, Pennsylvania.Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania; Magee-Women's Research Institute, Pittsburgh, Pennsylvania.Department of Gynecologic Oncology and Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pathology, Magee-Women's Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania; Magee-Women's Research Institute, Pittsburgh, Pennsylvania. Electronic address: rajkovic@upmc.edu.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27889101

Citation

Yatsenko, Svetlana A., et al. "Highly Heterogeneous Genomic Landscape of Uterine Leiomyomas By Whole Exome Sequencing and Genome-wide Arrays." Fertility and Sterility, vol. 107, no. 2, 2017, pp. 457-466.e9.
Yatsenko SA, Mittal P, Wood-Trageser MA, et al. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. Fertil Steril. 2017;107(2):457-466.e9.
Yatsenko, S. A., Mittal, P., Wood-Trageser, M. A., Jones, M. W., Surti, U., Edwards, R. P., Sood, A. K., & Rajkovic, A. (2017). Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. Fertility and Sterility, 107(2), 457-e9. https://doi.org/10.1016/j.fertnstert.2016.10.035
Yatsenko SA, et al. Highly Heterogeneous Genomic Landscape of Uterine Leiomyomas By Whole Exome Sequencing and Genome-wide Arrays. Fertil Steril. 2017;107(2):457-466.e9. PubMed PMID: 27889101.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. AU - Yatsenko,Svetlana A, AU - Mittal,Priya, AU - Wood-Trageser,Michelle A, AU - Jones,Mirka W, AU - Surti,Urvashi, AU - Edwards,Robert P, AU - Sood,Anil K, AU - Rajkovic,Aleksandar, Y1 - 2016/11/23/ PY - 2016/07/15/received PY - 2016/10/26/revised PY - 2016/10/26/accepted PY - 2016/11/28/pubmed PY - 2017/6/14/medline PY - 2016/11/28/entrez KW - MED12 mutation negative KW - Uterine leiomyoma KW - uterine leiomyosarcoma KW - whole exome sequencing KW - whole genome copy number analysis SP - 457 EP - 466.e9 JF - Fertility and sterility JO - Fertil. Steril. VL - 107 IS - 2 N2 - OBJECTIVE: To determine the genomic signatures of human uterine leiomyomas and prevalence of MED12 mutations in human uterine leiomyosarcomas. DESIGN: Retrospective cohort study. SETTING: Not applicable. PATIENT(S): This study included a set of 16 fresh frozen leiomyoma and corresponding unaffected myometrium specimens as well as 153 leiomyosarcomas collected from women diagnosed with uterine leiomyomas or leiomyosarcomas who underwent clinically indicated abdominal hysterectomy. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Whole exome sequencing and high-resolution X-chromosome and whole genome single nucleotide polymorphism microarray analyses were performed on leiomyoma samples negative for the known MED12 mutations and compared with their corresponding myometrium. Leiomyosarcoma specimens were examined for exon 2 MED12 mutations to evaluate the frequency of MED12 mutated leiomyosarcomas. RESULT(S): Our results indicate remarkable genomic heterogeneity of leiomyoma lesions. MED12-negative leiomyomas contain copy number alterations involving the Mediator complex subunits such as MED8, MED18, CDK8, and long intergenic nonprotein coding RNA340 (CASC15), which may affect the Mediator architecture and/or its transcriptional activity. We also identified mutations in a number of genes that were implicated in leiomyomagenesis such as COL4A6, DCN, and AHR, as well as novel genes: NRG1, ADAM18, HUWE1, FBXW4, FBXL13, and CAPRIN1. CONCLUSION(S): Mutations in genes implicated in cell-to-cell interactions and remodeling of the extracellular matrix and genomic aberrations involving genes coding for the Mediator complex subunits were identified in uterine leiomyomas. Additionally, we discovered that ∼4.6% of leiomyosarcomas harbored MED12 exon 2 mutations, but the relevance of this association with molecular pathogenesis of leiomyosarcoma remains unknown. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/27889101/Highly_heterogeneous_genomic_landscape_of_uterine_leiomyomas_by_whole_exome_sequencing_and_genome_wide_arrays_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(16)62958-8 DB - PRIME DP - Unbound Medicine ER -